Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209696 | 0.87 | NPSR1 (0.67) | LMNASMN1; SMN2NPSR1ALDH1A1KMT2A | |
| SCHEMBL24210195 | 0.84 | KMT2A (0.73) | LMNASMN1; SMN2NPSR1ALDH1A1KMT2A | |
| SCHEMBL24209876 | 0.83 | KMT2A (0.83) | SMN1; SMN2NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL24209776 | 0.82 | NPSR1 (0.77) | LMNASMN1; SMN2NPSR1ALDH1A1KMT2A | |
| SCHEMBL24210088 | 0.81 | KMT2A (0.83) | LMNASMN1; SMN2NPSR1ALDH1A1KMT2A | |
| SCHEMBL24209779 | 0.81 | KMT2A (0.76) | LMNASMN1; SMN2NPSR1ALDH1A1KMT2A | |
| SCHEMBL24209697 | 0.81 | ALDH1A1 (0.82) | LMNASMN1; SMN2NPSR1ALDH1A1KMT2A | |
| SCHEMBL24210095 | 0.80 | TSHR (0.85) | LMNASMN1; SMN2NPSR1ALDH1A1KMT2A | |
| SCHEMBL6277778 | 0.80 | SMN1; SMN2 (0.76) | LMNASMN1; SMN2NPSR1ALDH1A1APOBEC3G | |
| SCHEMBL24209778 | 0.79 | NPSR1 (0.67) | LMNASMN1; SMN2NPSR1ALDH1A1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | LMNA 4381/4885SMN1; SMN2 4699/4885NPSR1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.